Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Dansk
English
Søg efter indhold i Region Hovedstadens forskningsportal
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
A systematic review of bevacizumab efficacy in breast cancer
Iben Kümler
, Ole Grummedal Christiansen, Dorte Lisbet Nielsen
Afdeling for Kræftbehandling HGH
68
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'A systematic review of bevacizumab efficacy in breast cancer'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Breast Cancer
100%
Bevacizumab
100%
Phase II Trial
80%
Response Rate
60%
Neoadjuvant Setting
60%
Phase II Study
40%
Progression-free Survival
40%
Metastatic Setting
40%
PubMed
20%
Literature Search
20%
Molecular Mechanism
20%
Computer-based
20%
Time to Progression
20%
Overall Survival
20%
Predictive Biomarker
20%
Survival Benefit
20%
Cancer Invasion
20%
Cancer Treatment
20%
Angiogenesis
20%
Breast Cancer Treatment
20%
Phase II Clinical Trial
20%
Phase III Clinical Trial
20%
Cancer Metastasis
20%
Cancer Growth
20%
Bevacizumab Treatment
20%
Angiogenesis Inhibition
20%
Molecular Biomarkers
20%
Medicine and Dentistry
Systematic Review
100%
Bevacizumab
100%
Breast Cancer
100%
Biological Marker
33%
Progression Free Survival
33%
Clinical Trial
16%
Metastatic Carcinoma
16%
Tumor Invasion
16%
Overall Survival
16%
Angiogenesis
16%
Cancer Treatment
16%
Phase II Trials
16%
Cancer Growth
16%
Antiangiogenic Activity
16%
Nursing and Health Professions
Systematic Review
100%
Breast Cancer
100%
Bevacizumab
100%
Biological Marker
33%
Progression Free Survival
33%
Malignant Neoplasm
16%
Overall Survival
16%
Metastasis
16%
Cancer Growth
16%
Tumor Invasion
16%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Bevacizumab
100%
Biological Marker
33%
Progression Free Survival
33%
Malignant Neoplasm
16%
Clinical Trial
16%
Phase II Trials
16%
Overall Survival
16%
Tumor Invasion
16%
Metastasis
16%
Cancer Growth
16%